Evonik Industries Third Quarter 2024 Earnings: Misses Expectations
Evonik Industries (ETR:EVK) Third Quarter 2024 Results
Key Financial Results
- Revenue: €3.83b (up 1.6% from 3Q 2023).
- Net income: €223.0m (up from €96.0m loss in 3Q 2023).
- Profit margin: 5.8% (up from net loss in 3Q 2023).
- EPS: €0.48 (up from €0.21 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Evonik Industries Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 12%.
Looking ahead, revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany.
Performance of the German Chemicals industry.
The company's shares are down 6.9% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Evonik Industries you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Evonik Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:EVK
Evonik Industries
Produces specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America.
Excellent balance sheet established dividend payer.